Sugi Predict

Sugi Predict / Targets / JAK1

JAK1

Tyrosine-protein kinase JAK1 · P23458 · JAK1 on Sugi Atlas →

331,955 patent compounds predicted against JAK1, 175,543 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL99411 SCHEMBL99411 0.82 19/20
SCHEMBL99286 SCHEMBL99286 0.68 19/20
SCHEMBL100838 SCHEMBL100838 0.67 19/20
SCHEMBL100839 SCHEMBL100839 0.67 19/20
SCHEMBL100359 SCHEMBL100359 0.83 18/20
SCHEMBL100609 SCHEMBL100609 0.83 18/20
SCHEMBL98621 SCHEMBL98621 0.68 18/20
SCHEMBL100840 SCHEMBL100840 0.68 18/20
SCHEMBL101171 SCHEMBL101171 0.66 18/20
SCHEMBL102143 SCHEMBL102143 0.66 18/20
SCHEMBL100494 SCHEMBL100494 0.61 18/20
SCHEMBL101692 SCHEMBL101692 0.57 18/20
SCHEMBL101693 SCHEMBL101693 0.57 18/20
SCHEMBL99487 SCHEMBL99487 0.56 18/20
SCHEMBL98899 SCHEMBL98899 0.56 18/20
SCHEMBL99734 SCHEMBL99734 0.56 18/20
SCHEMBL101335 SCHEMBL101335 0.56 18/20
SCHEMBL101257 SCHEMBL101257 0.55 18/20
SCHEMBL101258 SCHEMBL101258 0.55 18/20
SCHEMBL100206 SCHEMBL100206 0.54 18/20

Clinical trials — most relevant to JAK1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis PHASE3UNKNOWN
Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata PHASE3COMPLETED
Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS) PHASE3ACTIVE_NOT_RECRUITING
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis PHASE3UNKNOWN
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas PHASE2RECRUITING
Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata PHASE2COMPLETED
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS) PHASE2RECRUITING
An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia PHASE2UNKNOWN
A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia PHASE2UNKNOWN
Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia PHASE2COMPLETED
Baricitinib in CPPD - the BAPTIST Study PHASE2NOT_YET_RECRUITING
Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors PHASE2RECRUITING
Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis PHASE2NOT_YET_RECRUITING
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo PHASE2RECRUITING
Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19 PHASE2UNKNOWN
JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial PHASE2RECRUITING
JAK Inhibitors for Solid Malignant Tumor Patients With Refractory Immune Checkpoint Inhibitors-related Dermatitis PHASE2NOT_YET_RECRUITING
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. PHASE2COMPLETED
Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma PHASE2COMPLETED
Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome PHASE1RECRUITING
Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions PHASE1COMPLETED
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients PHASE1RECRUITING
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea PHASE1COMPLETED
Itacitinib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease PHASE1RECRUITING
Ruxolitinib for Cancer Cachexia EARLY_PHASE1ACTIVE_NOT_RECRUITING
Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo nanUNKNOWN
Evaluate the Efficacy of Anti-Jak1 Inhibitors as Treatment for Patients With Aicardi-Goutières Syndrome nanCOMPLETED
Exploiting Leading Edge 7T MRI Brain Imaging to Decipher Olumiant's Mode of Analgesic Action in Rheumatoid Arthritis nanCOMPLETED
Cutaneous JAK in Vitiligo and Acne Vulgaris. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a JAK1 binder may also engage these)

ProteinNameSimilarity
P52332 — 1.000 P52332 →
O12990 — 1.000 O12990 →
Q62120 — 0.996 Q62120 →
Q75R65 — 0.996 Q75R65 →
Q62689 — 0.996 Q62689 →
JAK2 Tyrosine-protein kinase JAK2 0.996 landscape →
Q09178 — 0.995 Q09178 →
Q5RB23 — 0.994 Q5RB23 →
O19064 — 0.993 O19064 →
Q24592 — 0.993 Q24592 →
G5EFD2 — 0.989 G5EFD2 →
F1REV3 — 0.988 F1REV3 →
Q22070 — 0.988 Q22070 →
Q09639 — 0.988 Q09639 →
P26619 — 0.987 P26619 →
Q6GM71 — 0.987 Q6GM71 →
Q6GM53 — 0.987 Q6GM53 →
P70600 — 0.987 P70600 →
Q8BX57 — 0.987 Q8BX57 →
A2CEA7 — 0.987 A2CEA7 →
P43481 — 0.987 P43481 →
P32865 — 0.986 P32865 →
Q2HWD6 — 0.986 Q2HWD6 →
Q76II0 — 0.986 Q76II0 →
Q28317 — 0.986 Q28317 →
H2KZW3 — 0.986 H2KZW3 →
Q9QVP9 — 0.986 Q9QVP9 →
Q9VEZ5 — 0.986 Q9VEZ5 →
Q8AXC7 — 0.986 Q8AXC7 →
CHUK Inhibitor of nuclear factor kappa-B kinase subunit alpha 0.986 landscape →